Category Archives: Biotechnology

Preparing competent, competitive, and ethical leaders, Azusa Pacifics new Master of Science in Biotechnology equips graduates to make significant contributions to and profoundly influence this emerging science field. Set to launch in fall 2017 with a cohort of 24, the advanced degree distinguishes itself from counterparts at other institutions by approaching the discipline from a distinctly Christian worldview and instilling in students the ability to synthesize human need, potential, and responsibility. Graduates with this level of training find a wide-open marketplace eager to hire. Jobs in the biomedical industry show an upward trend throughout the country, and particularly in California, home to more than 50 percent of these companies. According to a 2014 report from Genetic Engineering and Biotechnology News, the industry expects significant job growth over the next decade in the areas of epidemiology, bioinformatics and genetic counseling, microbiology, biomedical engineering, and biomedical research. Nestled in the heart of the countrys second-largest cluster of bioscience businesses, APU offers students a distinct advantage that surpasses traditional internships and networking. A collaborative enterprise, this program partners APU with local bioscience companies, including Grifols Biologicals, Gilead Sciences, Johnson & Johnson, Allergan, and others. In addition to technical proficiency, APUs program also provides … Continue reading →

Morning Times JP Morgan Chase & Co Reiterates Overweight Rating for Puma Biotechnology Inc (PBYI) The Cerbat Gem Puma Biotechnology Inc logo J P Morgan Chase & Co restated their overweight rating on shares of Puma Biotechnology Inc (NYSE:PBYI) in a report issued on Tuesday morning. J P Morgan Chase & Co currently has a $89.00 target price on the ... Puma Biotechnology, Inc. (NasdaqGS:PBYI) Company Valuation & Investor ReviewUnion Trade Journal Puma Biotechnology (PBYI) Research Analysts' Weekly Ratings UpdatesBNB Daily (blog) Credit Suisse Group Reiterates $58.00 Price Target for Puma Biotechnology Inc (PBYI)Transcript Daily Stock Observer -Sports Perspectives -SEC.gov all 27 news articles » Originally posted here: JP Morgan Chase & Co Reiterates Overweight Rating for Puma Biotechnology Inc (PBYI) - The Cerbat Gem … Continue reading →

As if the stress of senior year isnt enough of a headache, Michael Vega began his final chapter of high school with a serious concussion. A soccer injury in May 2016 had mandated three months recovery time, stealing a summer of soccer training from the North Forsyth graduate. It hit me hard that I couldnt play, coming in with a big concussion, said Vega, a two-time all-conference award recipient. I had to jump right back into it. Vega, 17, was cleared to play in the final round of the Forsyth Cup last year, helping his team secure a victory in the championship round for the second year in a row, making school history. Vega, who spent three years on the varsity team, said one of his favorite high school moments was scoring the conference-winning goal against Asheboro High School as a sophomore. It was a great experience; theres nothing like it, said Vega, who plays goalie and center back. I knew half the guys from growing up, so its hard to say good-bye. While Vega said he will not play soccer in college, he will continue playing with the Hispanic League. Graduation is bittersweet, but Vega said he is glad … Continue reading →

Smith Asset Management Group LP Has $206000 Stake in Puma Biotechnology Inc (PBYI) The Cerbat Gem Puma Biotechnology logo Smith Asset Management Group LP continued to hold its stake in Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund ... Puma Biotechnology Inc (PBYI) Shares Bought by BNP Paribas ...Sports Perspectives Sivik Global Healthcare LLC Has $1,116,000 Position in Puma ...BBNS Puma Biotechnology Inc (PBYI) Lifted to Buy at Zacks Investment ResearchTranscript Daily Petro Global News 24 -FLBC News all 8 news articles » See the original post: Smith Asset Management Group LP Has $206000 Stake in Puma Biotechnology Inc (PBYI) - The Cerbat Gem … Continue reading →

The region's growing reputation as the centre for blue innovation has seen Tauranga successfully secure the International Marine Biotechnology Convention, which is being held in New Zealand for the first time. The Blue2Green Marine Biotechnology Convention' will take place from August 810. It will constitute a joint meeting between the newly formed Australia New Zealand Marine Biotechnology Society (a member of the International Marine Biotechnology Association), the International Conference on Coastal Biotechnology (convened in China), and the New Zealand Aquaculture Science Association. In addition, the Korean Society for Marine Biotechnology will be sending a special delegation. Chair of Coastal Science at the University of Waikato and Director of the Coastal Marine Field Station Professor Chris Battershill is also the Convention Chair. He says Blue2Green is designed to splice research interests, and explore new opportunities with a central theme of environmental sustainability linked to development of new high value marine industries. This convention will demonstrate how we can harness existing international excellence across marine biotechnological sciences to fast track sustainable wealth creation through novel application of marine biotechnologies, additionally examining how these very technologies can be used to aid repair or to strengthen environments under threat. With the Global Marine Biotechnology … Continue reading →

Puma Biotechnology (NYSE:PBYI) is inching closer to its transformation from a research and development (or R&D) biopharmaceutical company to a full-fledged commercial organization. This company which has in-licensed development and commercialization rights for oral and intravenous formulations of irreversible tyrosine kinase inhibitor or TKI, neratinib, and also another irreversible TKI, PB357, achieved the first major milestone for 2017 on May 24, 2017. On this day, FDA's Oncologic Drugs Advisory Committee or ODAC recommended approval for Nerlynx (neratinib) as extended adjuvant therapy for patients suffering with early stage, human epidermal growth factor receptor type 2 - positive or HER2-positive breast cancer after being previously treated with surgery and adjuvant treatment with Roche Holdings' (OTCQX:RHHBY) Herceptin (trastuzumab). Besides this indication, Puma Biotechnology expects neratinib to demonstrate efficacy in other cancers such a non small cell lung cancer and tumors related to expression or over-mutation in HER2 such as HER2-positive cancer, HER-2 cancer that has metastasized to brain, HER2-positive neoadjuvant breast cancer. Hence, there is high probability that Neratinib can prove to be a blockbuster drug for Puma Biotechnology. I believe this is a solid reason for considering the company as a favorable investment opportunity in 2017. In this article, I will explain … Continue reading →

The global biotechnology services outsourcing market is expected to reach USD 92.9 billion by 2025 Pharmaceutical industry has been adaptive of the function of outsourcing certain clinical and corporate functions as early as 2002. Among the services outsourced, clinical trial management and contract manufacturing were the forerunners. For instance, Johnson & Johnson was the first pharmaceutical company to outsource its applications development and maintenance (ADM). In 2015, over USD 50.0 billion was spent on pharmaceutical R&D activities majorly on oncology, diabetes, and autoimmune therapy classes, which is expected to propel the biotechnology services outsourcing market growth over the forecast period. Shrinking profit margins coupled with rising competition in the market space, and augmenting regulatory burden are other vital impact rendering factors. The pharmaceutical services outsourcing market is expected to register growth at a CAGR of 8.7% during the forecast period. On the other hand, pending immigration legislations in the U.S. may hinder business economics and outsourcing risks. Pharmaceutical and biotechnology industries in Europe are significantly investing in R&D in the recent year owing to rising demand for advanced medicines. This may be attributed to increasing aging population, incidence of chronic diseases, and communicable diseases. Further key findings from the study … Continue reading →

iShares NASDAQ Biotechnology Index (IBB) Receiving Somewhat ... The Cerbat Gem News headlines about iShares NASDAQ Biotechnology Index (NASDAQ:IBB) have trended somewhat positive recently, according to AlphaOne Sentiment. Vetr Inc. Lowers iShares NASDAQ Biotechnology Index (IBB) to HoldSports Perspectives Private Management Group Inc. Raises Stake in iShares NASDAQ Biotechnology Index (IBB)Stock Observer Bellevue Group AG Has $3.52 Million Stake in iShares NASDAQ Biotechnology Index (IBB)Transcript Daily Markets Daily -BBNS -BangaloreWeekly all 14 news articles » Originally posted here: iShares NASDAQ Biotechnology Index (IBB) Receiving Somewhat ... - The Cerbat Gem … Continue reading →

June 6, 2017 Never in the history of human existence has the opportunity to genetically modify or protect life been as great and accessible to anyone interested in the topic as it is today. Cures for human hereditary diseases. Designer babies. Glow-in-the-dark fish. Bioterrorism. Mosquitoes programmed to perish. The opportunities and risks are here now, but lagging are policies, ethical considerations and safety precautions needed to proceed prudently on an international scale. Arizona State University experts will delve into the issues presented by biotechnology during the annual International Biosafety and Biosecurity Symposium (SIBB) held this year in Morelia, Mexico, and organized by the Asociacin Mexicana de Bioseguridad (AMEXBIO), June 710. Were enhancing biosafety and biosecurity across international borders, said Irene Mendoza, associate biosafety officer with ASUs Office of Environmental Health and Safety, who will be one of the featured speakers at the symposium. Anything that affects Mexico, like the release of a pathogenic agent, can travel north and affect us. Although infectious diseases willbe addressed at the symposium, the ASU delegation will lead a technical discussion on gene editing and gene drive technologies, said David Gillum, ASU Environmental Health and Safety associate director and institutional biosafety officer. In simplest terms, … Continue reading →

Analyst Ratings The Case for and Against Puma Biotechnology, Inc. (PBYI) StockNewsJournal Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $83.65, up from yesterday's close by 2.07%. Given the stock's recent action, it ... What Should Investors Make Of The Trading Chart Of Puma Biotechnology, Inc. (PBYI)?NY Stock News Summary of Stock Move: Puma Biotechnology, Inc. (PBYI), Intrexon Corporation (XON)The Momentous News Adage Capital Partners Gp, LL Sells 507128 Shares of Puma Biotechnology Inc (PBYI) StockBNB Daily (blog) Analyst Ratings -The Cerbat Gem -StockNewsMagazine -Zacks all 38 news articles » See original here: The Case for and Against Puma Biotechnology, Inc. (PBYI) - StockNewsJournal … Continue reading →